922520-33-0

Basic information

• Product Name: Benzamide, 2-amino-4-methoxy-3-methyl-
• CAS NO: 922520-33-0
• Molecular Formula: C9H12N2O2
• Molecular Weight: 180.206
• Mol File: 922520-33-0.mol

Chemical Properties

• CAS DataBase Reference: Benzamide, 2-amino-4-methoxy-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-amino-4-methoxy-3-methyl-(922520-33-0)
• EPA Substance Registry System: Benzamide, 2-amino-4-methoxy-3-methyl-(922520-33-0)

Safety Data

• Hazardous Substances Data: 922520-33-0(Hazardous Substances Data)

Upstream product

• 102569-26-6 2-amino-4-hydroxy-3-methylbenzonitrile 
• 72817-85-7 4-Amino-5-cyan-3-methyl-salicylsaeure-ethylester 
• 72817-94-8 4-amino-5-cyano-2-hydroxy-3-methylbenzoic acid 
• 923274-68-4 2-amino-4-methoxy-3-methylbenzonitrile 

Downstream Products

• 1202186-95-5 C₁₅H₁₅N₃O₃ 
• 923274-69-5 4-Isopropylthiazole-2-carboxylic acid (6-carbamoyl-3-methoxy-2-methyl-phenyl)-amide 
• 922520-28-3 7-methoxy-8-methyl-2-(4-methoxyphenyl)-quinazolin-4-ol 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS

The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents

Novel NS3/4A protease inhibitors comprising quinazoline derivatives as P2 substituent were synthesized. High potency inhibitors displaying advantageous PK properties have been obtained through the optimization of quinazoline P2 substituents in three series exhibiting macrocyclic P2 cyclopentane dicarboxylic acid and P2 proline urea motifs. For the quinazoline moiety it was found that 8-methyl substitution in the P2 cyclopentane dicarboxylic acid series improved on the metabolic stability in human liver microsomes. By comparison, the proline urea series displayed advantageous Caco-2 permeability over the cyclopentane series. Pharmacokinetic properties in vivo were assessed in rat on selected compounds, where excellent exposure and liver-to-plasma ratios were demonstrated for a member of the 14-membered quinazoline substituted P2 proline urea series.

Macrocylic Inhibitors of Hepatitis C Virus

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6; — denotes an optional double bond;L is N or CRz; Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV